Desoximetasone Ointment USP, 0.25%

Cadila Healthcare Ltd.

Revision date : 2020-09-28

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.
Health risk rating 1
Safety risk rating 1
Environmental risk rating 1

General Information

Revision date

2020-09-28

Product name

Desoximetasone Ointment USP, 0.25%

Chemical name

Pregna-1, 4-diene-3, 20-dione, 9-fluoro-11, 21-dihydroxy-16- methyl-,(11b,16α)- Molecular Weight: 376.47 g/mol

1.2.1 Relevant identified uses

/ Therapeutic Desoximetasone Ointment USP, 0.25% is indicated for the relief Category of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses

1.2.2. Uses advised against

Desoximetasone ointment, 0.25% is contraindicated in those

Emergency telephone

Desoximetasone Ointment USP, 0.25% contains the active synthetic corticosteroid Desoximetasone

Icons in SDS

Company Information

company name

Cadila Healthcare Ltd.

Section 2

SECTION 2: Hazards identification

Dose and Administration Apply a thin film of Desoximetasone Ointment USP, 0.25% to the affected skin areas twice daily. Rub in gently. Adverse effects The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. In controlled clinical studies the incidence of adverse reactions was low (0.3%) for Desoximetasone Ointment USP, 0.25% and consisted of development of comedones at the site of application. Over Dose Effect Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects. Pregnancy Comments

Teratogenic Effects

Pregnancy Category C Corticosteroids have been shown to be teratogenic in laboratory animals when administered systemically at relatively low dosage levels. Some corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. Desoximetasone has been shown to be teratogenic and embryotoxic in mice, rats, and rabbits when given by subcutaneous or dermal routes of administration in doses 3 to 30 times the human dose of desoximetasone ointment USP, 0.25%. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids. Therefore, desoximetasone ointment USP, 0.25% should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time. Nursing Mothers: It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

SDS Library

Move your SDS library online today

Check Icon
Setup – Easy setup with our database of 16 million+ SDSs
Check Icon
Up-to-date – Your SDS get updated to latest versions.
Check Icon
Employee access – Tablets, Smartphones, or link from Corporate Intranet
Check Icon
Safety – One-click access to first aid information.
Check Icon
Labels – Generate Secondary Container Labels with just one click.